Johnson & Johnson (NYSE:JNJ) announced that it appointed Shawn Millerick as president of Vision Care, Americas. Millerick’s appointment went into effect on Nov. 11, 2024. He holds responsibility for defining strategy and driving growth for the company’s Vision Care portfolio in North America and LATAM. That includes the world’s leading contact lens family, Acuvue. Johnson […]
Johnson & Johnson
Johnson & Johnson MedTech’s participation in the Voluntary Improvement Program, supported by FDA
Encouraging medical-device manufacturers to go above and beyond to ensure regulatory compliance.
Partner content with ISACA. FDA studies have found that in the medical device industry, compliance alone is not enough to ensure improved quality indicators. Why? Because compliant medical-device manufacturers still report similar quality, complaint and performance issues as their uncompliant counterparts. “Part of the challenge is a cultural thing,” says Kim Kaplan, senior product manager […]
Johnson & Johnson MedTech inks distro deal to expand soft tissue solutions
Johnson & Johnson MedTech announced today that it entered into an exclusive commercial distribution agreement with Responsive Arthroscopy. The company agreed to a deal in the U.S. with Responsive Arthroscopy, which specializes in sports soft tissue repair solutions. Johnson & Johnson MedTech said the agreement strengthens its sports platform and enhances its soft tissue portfolio. […]
Johnson & Johnson wins FDA IDE for Ottava surgical robot
Johnson & Johnson MedTech announced today that the FDA granted its Ottava surgical robot investigational device exemption (IDE). The regulatory nod comes just under a month after the company announced that it submitted Ottava for IDE. It allows Johnson & Johnson MedTech to begin a clinical trial for the much-anticipated robotic platform at U.S. sites. […]
Johnson & Johnson MedTech wins FDA nod for Varipulse PFA
Johnson & Johnson MedTech announced today that the FDA approved its Varipulse pulsed field ablation (PFA) platform for treating AFib. Varipulse treats AFib with a single device that combines PFA with the Carto 3 mapping system. With approval, Johnson & Johnson joins Medtronic and Boston Scientific as companies with PFA technologies approved for treating AFib. […]
Shockwave Medical’s Javelin IVL catheter meets primary trial endpoints
Johnson & Johnson MedTech‘s Shockwave Medical unit today announced the first clinical outcomes associated with its Javelin catheter. Shockwave shared the first clinical outcomes associated with its Javelin peripheral intravascular lithotripsy (IVL) catheter system. It designed this novel, non-balloon-based lithotripsy platform to modify calcium and cross extremely narrowed vessels in patients with peripheral artery disease […]
The biggest cardiovascular tech stories from TCT 2024
The 2024 edition of the Transcatheter Cardiovascular Therapeutics (TCT) conference once again highlighted significant innovations in cardiovascular care. This year’s event in Washington, D.C., featured company updates on all types of technologies, including heart valves, access and closure devices, drug-eluting implants, intravascular lithotripsy (IVL), renal denervation (RDN) and more. Some of the biggest names in […]
Johnson & Johnson MedTech CIO says ‘see you later’
Johnson & Johnson (NYSE:JNJ) MedTech Global VP and Group Chief Information Officer Larry Jones is leaving the world’s second-largest medical device manufacturer. “After 35 incredible years at Johnson & Johnson, I find myself reflecting on the remarkable journey we’ve experienced together,” Jones said on LinkedIn today. “To my friends and partners throughout this journey, this […]
Johnson & Johnson completes pilot enrollment in Omnypulse trial
Johnson & Johnson MedTech today announced the completed enrollment in the pilot phase of a clinical trial for its Omnypulse pulsed field ablation platform. The OMNY-AF clinical trial evaluates the investigational platform for treating symptomatic paroxysmal AFib in the U.S. and Australia. The single-arm, multi-center trial completed the pilot phase enrollment of 30 patients. Johnson […]
Johnson & Johnson has positive Impella ECP heart pump data
Johnson & Johnson MedTech reported positive data for the Abiomed Impella ECP transvalvular axial flow pump with compressible pump architecture. Investigators presented results at Transcatheter Cardiovascular Therapeutics (TCT) 2024 in Washington, D.C. Dr. Amir Kaki led the FDA IDE study — the first completed pivotal trial for Impella ECP — as principal investigator. J&J said […]
Johnson & Johnson reports first commercial Varipulse use in Canada
Johnson & Johnson MedTech today announced the first completed commercial case with its Varipulse platform in Canada. The company said in a post on LinkedIn that doctors at the Ottawa Heart Institute completed the first commercial case with Varipulse. J&J said the procedure “marks a significant step forward” in the treatment of AFib with the […]
